--- title: "Hong Kong's Department of Health: Will intensify efforts to promote the development of traditional Chinese medicine and build Hong Kong into a bridgehead for traditional Chinese medicine and herbal medicine to reach the world" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/275855480.md" description: "The Hong Kong Department of Health announced that it will intensify efforts to promote the development of traditional Chinese medicine, aiming to build Hong Kong into a bridgehead for traditional Chinese medicine and herbal medicine to reach the world. Professor Lo Chung-mau, the Secretary for Health, stated in the Legislative Council that the development of traditional Chinese medicine in Hong Kong has entered a new stage. The government will implement the \"Blueprint for the Development of Traditional Chinese Medicine,\" covering areas such as traditional Chinese medicine services, professional and cultural inheritance, proposing eight goals and 20 actions aimed at improving the quality of medical services and health levels for citizens" datetime: "2026-02-13T06:02:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275855480.md) - [en](https://longbridge.com/en/news/275855480.md) - [zh-HK](https://longbridge.com/zh-HK/news/275855480.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275855480.md) | [English](https://longbridge.com/en/news/275855480.md) # Hong Kong's Department of Health: Will intensify efforts to promote the development of traditional Chinese medicine and build Hong Kong into a bridgehead for traditional Chinese medicine and herbal medicine to reach the world According to Zhitong Finance APP, on February 13, Professor Lo Chung-mau, Secretary for Health of Hong Kong, spoke at the Legislative Council's Health Affairs Committee meeting, stating that the development of traditional Chinese medicine (TCM) in Hong Kong has entered a new milestone, with multiple key flagship projects and policy measures being implemented. In December last year, the Hong Kong government announced the "Blueprint for the Development of Traditional Chinese Medicine," which is the first policy document from the Hong Kong government specifically addressing the development of TCM in Hong Kong. It outlines the vision for TCM development in Hong Kong, covering five areas: TCM services, TCM professionals, Chinese medicine development, cultural heritage, and going global, proposing eight goals and 20 actions. This "Blueprint" has three major concepts. First, it aims to leverage the advantages of TCM to strengthen local medical services, expanding the development of TCM at the primary, secondary, and tertiary healthcare levels, while educating the public to understand when to appropriately use TCM services. Second, it aligns with the national strategy for TCM development, integrating TCM deeply into the healthcare system and promoting the new productive forces of TCM through scientific research and innovation. Third, it seeks to capitalize on Hong Kong's advantages in the healthcare system, regulatory framework, and standard-setting, allowing Hong Kong to become a stronghold for the country in promoting TCM globally under the "One Country, Two Systems" principle. The "Blueprint" sets a clear direction for the development of TCM in Hong Kong, and the Hong Kong Department of Health will actively follow up on all actions proposed in the "Blueprint." Meanwhile, two flagship institutions for the development of TCM in Hong Kong, the Hong Kong Chinese Medicine Hospital and the Hong Kong Government Chinese Medicine Testing Center, have also been gradually put into service since December 11 last year. Professor Lo pointed out that the Chinese Medicine Hospital is Hong Kong's first hospital primarily focused on TCM services. In its first year of operation, the hospital will provide outpatient and day inpatient services, fully developing six major TCM specialties and 12 specialized (disease-specific) projects, and will begin offering inpatient services in December this year. Since the hospital opened for appointment services, public response has been very enthusiastic, with the outpatient services funded by the Hong Kong government consistently reaching full capacity and having increased quotas three times, attracting patients from several countries overseas seeking treatment. Starting in April this year, more renowned TCM experts from both local and mainland China will join the clinical team at the Chinese Medicine Hospital to participate in medical education and research work. In line with the policy direction proposed in the "Blueprint," the Chinese Medicine Hospital aims to further establish a "Hong Kong model" of clinical services that focuses on pure TCM, TCM as the main approach, and collaboration between TCM and Western medicine, promoting the development of TCM locally, in the Guangdong-Hong Kong-Macao Greater Bay Area, and internationally. As for the Hong Kong Government Chinese Medicine Testing Center, after the completion and commissioning of its permanent building, it will enhance Chinese medicine testing methods, strengthen the development of Chinese medicine standards, and enhance cooperation and exchanges between Hong Kong and overseas by introducing advanced technology and talent, aiming to develop Hong Kong into an international center for Chinese medicine testing and quality control. In just two months of service, the Chinese Medicine Hospital and Testing Center have collectively held over 130 industry and public guided tours, playing an important role in promoting TCM. The "Blueprint" mentions encouraging cross-professional collaboration. With the relevant amendments to the "Registered Medical Practitioners Ordinance" passed by the Legislative Council last year, registered medical practitioners, including physiotherapists, occupational therapists, radiographers, and medical laboratory technologists, can now accept referrals from registered TCM practitioners. The Hong Kong Chinese Medicine Council and the Professional Medical Practitioners Management Board have immediately begun discussions to revise professional codes and publish medical referral guidelines. The referral arrangements have promoted cross-professional collaboration at the clinical level and deepened the role of TCM in the healthcare system On the basis of the above achievements, the Hong Kong government will intensify efforts to promote the high-quality, high-level, and comprehensive development of traditional Chinese medicine (TCM) in Hong Kong, allocate more resources, and implement policy measures to realize the vision proposed in the "Blueprint"—to inherit the wisdom of TCM, leverage national development experience and resources, utilize TCM to provide Hong Kong citizens with better and more comprehensive medical services, enhance health levels, and simultaneously build Hong Kong into a bridgehead for TCM and traditional Chinese medicine to reach the world ### 相關股票 - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-HK/quote/589720.CN.md) - [CHINARES PHARMA (03320.HK)](https://longbridge.com/zh-HK/quote/03320.HK.md) - [TRT (600085.CN)](https://longbridge.com/zh-HK/quote/600085.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-HK/quote/159929.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [MODERN CHI MED (01643.HK)](https://longbridge.com/zh-HK/quote/01643.HK.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [TONGRENTANGCM (03613.HK)](https://longbridge.com/zh-HK/quote/03613.HK.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [E Fund CSI HK Equities Medical and Health Integration ETF (513200.CN)](https://longbridge.com/zh-HK/quote/513200.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [Taikang CNI Public Health and Medical Health ETF (159760.CN)](https://longbridge.com/zh-HK/quote/159760.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [GF CSI All Share Health Care ETF (159938.CN)](https://longbridge.com/zh-HK/quote/159938.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) ## 相關資訊與研究 - [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-HK/news/281501537.md) - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md) - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md) - [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-HK/news/281458440.md) - [Tong Ren Tang Subsidiary Posts Lower 2025 Profit as Revenue and Margins Decline](https://longbridge.com/zh-HK/news/279954067.md)